GenEmbryomics

Executive Summary

GenEmbryomics is an Australian biotech company advancing preimplantation genetic testing (PGT) through its Panacea GenomeScreen™ platform, which employs whole-genome sequencing (PGT-WGS) to comprehensively screen embryos for aneuploidy, mosaicism, and mutations across over 3,200 disease-associated genes. Founded in 2020 and based in Melbourne, the company aims to reduce the incidence of inherited disorders in IVF pregnancies by delivering detailed, clinically actionable genomic insights to IVF clinics and patients. Its technology stands out by combining aneuploidy screening with extensive monogenic disease detection in a single test, potentially improving embryo selection and reducing the need for multiple procedures. With a 10-50 employee count and no disclosed funding, GenEmbryomics operates in the reproductive health and genetic disease prevention sectors, targeting a growing IVF market that increasingly values comprehensive genetic screening.

Upcoming Catalysts (preview)

• Q1 2027Publication of clinical validation study for Panacea GenomeScreen70% success
• Q2 2026Partnership with major IVF clinic network in Australia/Asia50% success
• Q3 2026Regulatory approval from TGA for clinical use in Australia60% success